Synta Pharmaceuticals Corp. SNTA today provided clinical
updates and reported financial results for the second quarter ended June
30, 2013.
Clinical Updates
Our lead clinical candidate is ganetespib, a selective inhibitor of the
Hsp90 chaperone protein, which is being evaluated in over 25 clinical
trials that have enrolled over a thousand patients to date, including
our GALAXY program in lung cancer and our ENCHANT program in breast
cancer.
The GALAXY program in lung cancer
At the 2013 meeting of the American Society of Clinical Oncology (ASCO),
investigators presented results from an interim analysis
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in